| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a14ad758e899b200390f1ab62878330c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92e51270ab4c418ea4da39dfd889ff97 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-01037
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1205 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
1996-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06ad0177de5c97dfe9e393f1e3d95647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4349f625af94017eeb755b370a4592c6 |
| publicationDate |
1998-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0862619-A1 |
| titleOfInvention |
Pskh-1 ribozymes and uses in disease treatment |
| abstract |
Disclosed is a purified full-length cDNA molecule encoding putative serine kinase enzyme (PSKH-1), and the expression of the cDNA in a recombinant host cell to produce substantially purified PSKH-1, per se. Inactivation of PSKH-1 pre-mRNA or PSKH-1 mRNA halts DNA synthesis and cell division. Also disclosed are ribozymes capable of cleaving PSKH-1 pre-mRNA or mRNA and thus deactivating PSKH-1 translation. Ribozymes of the hammerhead and hairpin motifs, and various compositions containing same, are also disclosed. The ribozymes compositions are used in the treatment of mammalian patients suffering from diseases or medical conditions characterized by abnormal cell proliferation or growth such as cancer and various non-malignant diseases or medical conditions such as autoimmue diseases, allograft rejection and atherosclerosis. |
| priorityDate |
1995-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |